Clinical trial · no report yet · Phase 1/Phase 2
STARLIGHT-1
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- NCT06343311 ↗
- Recruiting
- Estrella Immunopharma, Inc.
- 5 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 3 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- B-Cell Non-Hodgkin's Lymphoma (NHL); Lymphoma, Non-Hodgkins; Lymphomas Non-Hodgkin's B-Cell; Non-Hodgkin Lymphoma; Non-Hodgkin's Lymphoma; Large B-Cell Lymphoma; Lymphoma, Non-Hodgkin's, Adult; Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma; Lymphoma, Non-Hodgkin; HIV Associated Lymphoma; CNS Lymphoma; High-grade B-cell Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- EB103
- Arms
- EB103 · Experimental
- Enrollment
- 27 (estimated)
- Primary outcomes
- To assess the safety and tolerability of EB103.
- To determine the Recommended Phase II Dose (RP2D) of EB103 (in Phase 1, Dose Escalation)
- Sponsor
- Estrella Immunopharma, Inc. with Eureka Therapeutics Inc.
- Start
- Jun 1, 2024
- Primary completion
- Jul 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06343311 · updated Oct 1, 2026